Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Key Highlights
- ➤Q3 2026 results scheduled for November 5 before U.S. market open
- ➤Conference call and webcast scheduled for 8:30 a.m. ET November 5
- ➤Xeris has three commercially available products: Recorlev, Gvoke, and Keveyis
- ➤XP-8121 is Phase 3-ready for once-weekly hypothyroidism treatment
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business highlights for the third quarter ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 5, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s third-quarter 2026 financial and operational results and business highlights.
Get started
Create a free account to read the full story.